SELLAS Life Sciences Group
New York
About SELLAS Life Sciences Group
Galena Biopharma, Inc. (Galena) is a biotechnology company focused on discovering, developing and commercializing therapies addressing unmet medical needs using targeted biotherapeutics. The Company is pursuing the development of cancer therapeutics using peptide-based immunotherapy products, including its main product candidate, NeuVaxTM (E75), for the treatment of breast cancer and other tumors. NeuVax is a peptide-based immunotherapy intended to reduce the recurrence of breast cancer in low-to-intermediate HER2-positive breast cancer patients not eligible for trastuzumab (Herceptin; Genentech/Roche). In January 2014, Galena Biopharma Inc acquired Mills Pharmaceuticals, which has the worldwide rights to GALE-401 (Anagrelide CR), a patented, controlled release formulation of anagrelide.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $89.1M
- Funding stage: IPO
- Last round: Post-IPO Equity (Oct 2025)
- Ticker: nasdaq:SLS
- Website: sellaslifesciences.com
- Phone: +118558554253
Industries & Categories
Biotechnology, Health Diagnostics, Medical
Social Profiles
Canonical: https://fsome.com/organization/sellas-life-sciences-group-86689 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.